SCHEMBL1470360

SCHEMBL1470360

Cc1nc(Cl)c2ccccc2c1CCl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 2/20 0.36
GPR3 P46089 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
POLB P06746 1/20 0.35
CYP2A6 P11509 1/20 0.34
LMNA P02545 2/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
APEX1 P27695 1/20 0.34
MAPK1 P28482 1/20 0.34
PMP22 Q01453 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
BBOX1 O75936 1/20 0.33
FTO Q9C0B1 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11154118 0.78 SMN1; SMN2 (0.56) ALDH1A1KDM4EPOLBLMNAMAPT
SCHEMBL12072357 0.75 GPR3 (0.40) L3MBTL1ALDH1A1GPR3RXFP1POLB
SCHEMBL7427455 0.75 LMNA (0.47) L3MBTL1ALDH1A1KDM4EGPR3RXFP1
SCHEMBL4832538 0.73 GAA (0.41) L3MBTL1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL1470347 0.72 GPR3 (0.38) L3MBTL1ALDH1A1KDM4EGPR3RXFP1
SCHEMBL12335687 0.72 EGLN1 (0.45) L3MBTL1GPR3RXFP1LMNABBOX1
SCHEMBL5475190 0.72 HSD17B10 (0.42) L3MBTL1ALDH1A1KDM4EKMT2AGPR3
SCHEMBL31409925 0.72 GPR3 (0.38) L3MBTL1ALDH1A1KDM4EGPR3RXFP1
SCHEMBL19065035 0.72 L3MBTL1 (0.50) L3MBTL1ALDH1A1KDM4EKMT2ACYP2A6
SCHEMBL29367505 0.71 L3MBTL1 (0.67) L3MBTL1ALDH1A1KDM4EKMT2AGPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745024-B1 1-ARYL-4-SUBSTITUTED ISOQUINOLINES NOVARTIS INT PHARM LTD (BM) 2012-04-25 EP disclosed
US-7915288-B2 1-aryl-4-substituted isoquinolines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-03-29 US disclosed
EP-1745024-A4 1-ARYL-4-SUBSTITUTED ISOQUINOLINES NEUROGEN CORP (US) 2008-01-09 EP disclosed
US-20070249665-A1 1-aryl-4-substituted isoquinolines NEUROGEN CORPORATION (US) 2007-10-25 US disclosed
CN-1980895-A 1-aryl-4-substituted isoquinolines NEUROGEN CORP (US) 2007-06-13 CN disclosed
EP-1745024-A1 1-ARYL-4-SUBSTITUTED ISOQUINOLINES NEUROGEN CORPORATION (US) 2007-01-24 EP disclosed
WO-2005110991-A1 1-ARYL-4-SUBSTITUTED ISOQUINOLINES NEUROGEN CORPORATION (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249665-A1 1-aryl-4-substituted isoquinolines C3AR1, C5AR1, C5AR2 L3MBTL1 3234/4885ALDH1A1 1164/4885KDM4E 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.